Pharmaceutical company Mankind Pharma has closed a deal to acquire Bharat Serum and Vaccines Limited (BSV) for Rs 13,768 crore. The company provided this information on Wednesday. According to PTI News, the company said that this strategic move is a significant leap for the company, which has established it as the leader in the Indian women’s health and reproductive medicine market. It also provided access to other high barrier to entry products in the critical care segment with an established complex R&D technology platform.
Mankind Pharma’s position will be strengthened
According to the news, BSV has developed recombinant and niche biologics products in-house, demonstrating its strong R&D capabilities and boasts of a strong portfolio of branded products in women’s health, reproduction, critical care and immunoglobulins. . Rajeev Juneja, Vice Chairman and Managing Director, Mankind Pharma, said: “Today we warmly welcome BSV’s 2,500+ members to the Mankind family, adding a new chapter to our exciting journey and laying the foundation for accelerated growth.
Widespread access to complex treatments will be guaranteed
Sanjeev Nawangul, MD & CEO of BSV, said being part of the Mankind Pharma family makes BSV bigger, stronger and better. Now, together we will be able to ensure widespread access to our complex, unique and indigenously developed treatments to millions of patients in India and around the world. Together we will unlock new possibilities, explore opportunities and maximize potential that will help us achieve our business priorities and objectives. In July this year, Mankind announced that it would acquire 100 percent of the shares of BSV.
Latest business news
